- Home
- MGTX
as 06-20-2025 4:00pm EST
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 520.8M | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 451.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.85 - $8.75 | Next Earning Date: | 08-11-2025 |
| Revenue: | $34,508,000 | Revenue Growth: | 203.23% |
| Revenue Growth (this year): | 365.04% | Revenue Growth (next year): | 73.18% |
Stock Insider Trading Activity of MeiraGTx Holdings plc (MGTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Giroux Richard | MGTX | CFO & COO | Apr 22 '25 | Sell | $6.00 | 24,000 | $144,000.00 | 882,494 | |
| Forbes Alexandria | MGTX | PRESIDENT & CEO | Apr 8 '25 | Sell | $5.34 | 47,500 | $253,650.00 | 1,408,983 |
Latest MeiraGTx Holdings plc News
MGTX Breaking Stock News: Dive into MGTX Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Chardan Adjusts MeiraGTx Price Target to $35 From $38, Maintains Buy Rating
GlobeNewswire
a month ago
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Zacks
a month ago
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
a month ago
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Friday Afternoon
MT Newswires
a month ago
MeiraGTx Says FDA Granted RMAT Designation to AAV-GAD for Treating Parkinson's; Shares Up Pre-Bell
GlobeNewswire
a month ago
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
MT Newswires
2 months ago
Top Premarket Decliners
Compare MGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGTX MeiraGTx Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.